Collecting blood samples from lung cancer patients on targeted therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study involves adult patients with non-small cell lung cancer (NSCLC) who are being treated with tyrosine kinase inhibitors (TKIs). The study aims to collect repeated blood samples at various intervals during treatment to conduct liquid mutation testing and pharmacokinetic analysis. Blood will be drawn during routine clinical visits, and additional samples will be taken when patients undergo standard biopsies. The goal is to monitor mutations and resistance mechanisms without interfering with standard care practices.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Able to understand the written informed and able to give informed consent
* Locally advanced or metastatic NSCLC with oncogenic driver mutation
* Treatment with TKI according to standard of care

Exclusion Criteria:

* Unable to draw blood for study purposes

Where it's running

• Erasmus MC
  Rotterdam, Netherlands Recruiting

Study contacts

• Principal investigator: Anne-Marie Dingemans, MD, PhD — Erasmus Medical Center
• Study coordinator: Anne-Marie Dingemans, MD, PhD
• Email: a.dingemans@erasmusmc.nl
• Phone: +31107040704

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining Befotertinib with Bevacizumab or Chemotherapy for Lung Cancer Treatment

  This study is testing if a new lung cancer treatment combining befotertinib with either bevacizumab or chemotherapy can help patients with early-stage cancer that has an EGFR mutation feel better before surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT06755684

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.